Literature DB >> 8390121

[Current status of therapy of CNS metastases of germ cell tumors].

C Clemm1, A Gerl, T G Wendt, B Pöllinger, P A Winkler, W Wilmanns.   

Abstract

The incidence of CNS metastases in germ cell tumors is 2-5% and in very advanced disease over 20%. We report on 37 patients in whom CNS metastases were diagnosed with the CAT scanner. Twenty-nine patients were subsequently treated. In 19 cases, treatment consisted of radiotherapy, 1 patient was only operated on, and in 9 cases patients received combined surgery and radiotherapy. Two patients had seminomatous germ cell tumors, 27 patients non-seminomatous tumors. HCG levels were high in 11 cases. In 31 patients the disease was in the advanced stages; in 6 the disease was at the early stage. If there was just a solitary tumor, operation was the preferred mode of treatment. Radiotherapy consisted of 50 GY whole-brain irradiation, with a tumor saturation up to 60 GY. In 2 cases we suspected radiogenic necrosis. There were no other severe side effects. Of the 37 patients, 4 obtained a long-term cure (observation time 34-90 months). Therapy must take all methods of treatment into consideration and should only be carried out in fully equipped medical centers. Only then can we hope to obtain long-term cures in individuals with this usually fatal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390121

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  3 in total

1.  [Treatment of cerebral metastasis in patients with testicular germ cell tumors].

Authors:  J Classen
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

2.  [Register study for treatment of brain metastases of malignant testicular tumors].

Authors:  J T Hartmann; P Albers; C Clemm; R Souchon; L Weissbach; M Bamberg; C Bokemeyer
Journal:  Urologe A       Date:  1998-07       Impact factor: 0.639

3.  Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer.

Authors:  A Gerl; C Clemm; P Kohl; A Schalhorn; W Wilmanns
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.